Skip to main content
. Author manuscript; available in PMC: 2008 Apr 3.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1458–1465. doi: 10.1167/iovs.06-0438

Table 2.

Characteristics of the Participants with and without Successful MPOD Estimates

With Measurements
Without Measurements
n (%)* Age (Mean ± SD) Range (y) n (%)* Age (mean ± SD) Range (y)
Total 183(82) 78.9 ± 3.2 69–86 39(18) 79.8 ± 3.1 76–86
By gender
 Male 89(84) 79.5 ± 3.1 70–86 17(16) 79.5 ± 2.5 76–85
 Female 94(81) 78.3 ± 3.3 69–85 22(19) 80.1 ± 3.6 76–86
By race
 White 148(87) 78.8 ± 3.3 69–85 22(13) 79.5 ± 3.1 76–85
 Black 35(67) 79.1 ± 3.0 76–86 17(33) 80.4 ± 3.1 76–86
By lutein supplement use§
 Users 62(83) 78.3 ± 3.5 69–85 13(17) 79.5 ± 2.9 76–85
 Nonusers 120(82) 79.1 ± 3.1 72–86 26(18) 80.0 ± 3.2 76–86
*

Percentage of total (n = 222) and by gender, race, or lutein supplement use subgroup.

Unpaired two-tailed t-test, P = 0.008.

χ2 test, P = 0.0007.

§

Lutein supplement use status could not be ascertained for one participant.